Beta Bionics Q2 net sales up 38% to $32M; gross margin expands 524 bps to 59%

Beta Bionics, Inc.

Net sales $32.0M, up 38% YoY; PBP channel sales surged 153% to $11.6M.
Gross margin 59.0%, up 524 bps from 53.8% in Q2 2025.
Net loss $23.4M (negative 73% of sales) vs $16.9M (negative 73%) YoY.
Adjusted EBITDA negative $17.7M (negative 55% of sales) vs negative $14.5M (negative 63%).
Cash and investments $225.2M as of June 30, 2026; full year 2026 guidance updated (specifics not provided in excerpt).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.